Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences has announced that substantial shareholder Shanghai Tanying Investment Partnership (LP), which currently holds 59,459,326 A shares representing about 5.79% of the company’s total share capital, plans to reduce its stake due to fund maturity and liquidity needs. Under approved share reduction policies for venture capital fund shareholders, Shanghai Tanying intends to sell up to 20,533,797 shares, or no more than 2% of Junshi’s total share capital, via block trading, a move that may modestly increase the stock’s free float while signaling that the shareholder remains optimistic about the company’s long‑term prospects despite trimming its position.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company listed in Hong Kong and on the Shanghai Stock Exchange’s STAR Market, focusing on innovative drug research, development and commercialization. Its shareholder base includes institutional investors such as private equity and venture capital funds, reflecting its positioning in China’s high‑growth biotech and life sciences sector.
Average Trading Volume: 4,227,520
Technical Sentiment Signal: Sell
Current Market Cap: HK$36.27B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.